Previous Close | 0.4300 |
Open | 0.4300 |
Bid | 0.1500 |
Ask | 3.2000 |
Strike | 7.00 |
Expire Date | 2024-06-21 |
Day's Range | 0.4300 - 0.4300 |
Contract Range | N/A |
Volume | |
Open Interest | 186 |
By Jeremy Golden, Benzinga NEEDHAM, MA / ACCESSWIRE / June 3, 2024 / Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ:CADL) reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline ...
FDA Orphan Designation provides CAN-3110 certain developmental financial incentives, with potential for up to 7 years of marketing exclusivity in the United States, if approvedCAN-3110 phase 1b data on the feasibility and safety of multiple doses of CAN-3110 will be featured in poster presentation at 2024 ASCO Annual Meeting NEEDHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on deve
Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.